`
`Not for Publication
`
`
`
`
`UNITED STATES DISTRICT COURT
`DISTRICT OF NEW JERSEY
`
`Civil Action No. 20-3754
`
`OPINION
`
`
`
`
`
`
`
`SCHWAB CAPITAL TRUST on behalf of its
`series SCHWAB TOTAL STOCK MARKET
`INDEX FUND, SCHWAB HEALTH CARE
`FUND, SCHWAB DIVIDEND EQUITY FUND,
`SCHWAB LARGE-CAP GROWTH FUND,
`SCHWAB S&P 500 INDEX FUND, SCHWAB
`CORE EQUITY FUND, SCHWAB HEDGED
`EQUITY FUND, SCHWAB U.S. LARGE-CAP
`GROWTH INDEX FUND, and SCHWAB
`FUNDAMENTAL US LARGE COMPANY
`INDEX FUND; et al.;
`
`
`Plaintiffs;
`
`v.
`
`CELGENE CORPORATION; et al.;
`
`
`Defendants.
`
`
`
`
`John Michael Vazquez, U.S.D.J.
`
`
`
`Plaintiffs filed this matter after deciding not to participate as a class member in In re
`
`Celgene Corporation Securities Litigation, Civil Action No. 18-4772 (the “Class Action”), a class
`
`action presently pending before this Court. Plaintiffs in both matters allege that Celgene
`
`Corporation (“Celgene”) and several of its officers and/or employees engaged in fraud under
`
`Section 10(b) and Rule 10b-5 of the Securities Exchange Act of 1934 (the “Exchange Act”), 15
`
`U.S.C. § 78a et seq., as to public statements relating to two drugs in Celgene’s new product
`
`pipeline. Currently pending before the Court is Defendants’ motion to dismiss Plaintiffs’
`
`Complaint for failure to state a claim pursuant to Federal Rule of Civil Procedure 12(b)(6), as well
`
`as the Private Securities Litigation Reform Act of 1995 (“PSLRA”), 15 U.S.C. § 78u et seq. D.E.
`
`
`
`Case 2:20-cv-03754-JMV-JBC Document 18 Filed 03/22/21 Page 2 of 23 PageID: 1499
`
`6. The Court reviewed the parties’ submissions in support and in opposition,1 and decided the
`
`motion without oral argument pursuant to Fed. R. Civ. P. 78(b) and L. Civ. R. 78.1(b). For the
`
`reasons stated below, Defendants’ motion is GRANTED in part and DENIED in part.
`
`I.
`
`INTRODUCTION
`
`A. Background
`
`Plaintiffs’ allegations here mirror those pled in the Class Action. In fact, the vast majority
`
`of Plaintiffs’ Complaint is copied from the operative Complaint in the Class Action (the “Class
`
`Action Complaint”). As a result, the Court incorporates the detailed factual background from its
`
`December 19, 2019 Opinion that granted in part and denied in part the motion to dismiss the Class
`
`Action Complaint, D.E. 75, into the present Opinion.
`
`
`
`Briefly, Celgene manufactures and sells the multiple myeloma drug Revlimid, which
`
`between 2014 and 2016, accounted for more than sixty percent of Celgene’s total net sales.2
`
`Compl. ¶ 1. The Revlimid patent expires in 2022. Id. Plaintiffs allege that Defendants3 made
`
`
`1 Defendants’ moving brief will be referred to as “Defs. Br.,” D.E. 6-1; Plaintiffs’ opposition will
`be referred to as “Plfs. Opp,” D.E. 10; and Defendants’ reply will be referred to as “Defs. Reply,”
`D.E. 17.
`
` 2
`
` The facts are derived from Plaintiffs’ Complaint. D.E. 1. When reviewing a Rule 12(b)(6)
`motion to dismiss, the Court accepts as true all well-pleaded facts in the complaint. Fowler v.
`UPMC Shadyside, 578 F.3d 203, 210 (3d Cir. 2009). Additionally, a district court may consider
`“exhibits attached to the complaint and matters of public record,” as well as “an undisputedly
`authentic document that a defendant attaches as an exhibit to a motion to dismiss if the plaintiff’s
`claims are based on the document.” Pension Ben. Guar. Corp. v. White Consol. Indus., Inc., 998
`F.2d 1192, 1196 (3d Cir. 1993).
`
` 3
`
` The defendants in this matter are Celgene; Scott A. Smith, Celgene’s President and Chief
`Operating Officer from April 1, 2017 until April 2, 2018, Compl. ¶ 52; Terrie Curran, President of
`the Global Inflammatory & Immunology (“I&I”) franchise during the time frame at issue, id. ¶ 53;
`and Philippe Martin, Managing Director of Receptos and Celgene’s Corporate Vice President
`during the relevant time frame, id. ¶ 54.
`
`
`
`2
`
`

